QualityStocks News – RXi Pharmaceuticals Appoints Seasoned Medical Experts to Scientific Advisory Board

Wiltshire is an London-based artist who draws city panoramas after getting a glimpse of the location from a helicopter. The precise details of his panoramas — done just from his memory — are often startling. Past projects have been the subject of documentaries, and his career has been covered by CBS since 1988, when he was a child prodigy. He is the author of three books, including his latest, “Floating Cities.”

Scottsdale, AZ (PRWEB) July 14, 2012

QualityStocks want to highlight RXi Pharmaceuticals Corporation, a publicly traded biotechnology company focused on learning, developing, and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or RNAi, have fantastic promise because of their ability to silence, or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.

In the companys news yesterday,

Biotech company RXi Pharmaceuticals announced Dr. Jeannette Graf and Dr. Leroy Young have been added to its Scientific Advisory Board where their experience and research expertise will contribute to the ongoing development of the companys lead compound.

Dr. Graf is a board certified, clinical and research dermatologist with a private practice in Fantastic Neck, NY. She is an assistant clinical professor of Dermatology at the Mount Sinai School of Medicine in New York; an accomplished product developer; and author of best-selling Stop Aging, Start Living. Dr. Graf has made multiple television and news appearances on national news and well loved cable programs including: The Dr. Oz Show, Fox And Friends, MSNBC, The View, Inside Edition, Focus On Women, CBS Early Show, Excellent Morning America, Mike and Juliet, and Sirius Radio. In addition, she is quoted in numerous national print and online publications.

Dr. Young is the director of the BodyAesthetic Research Center in St. Louis, Missouri. He is board certified in General Surgery and Plastic Surgery, and has held several academic positions in the fields of surgery and plastic surgery at the Washington School of Medicine in St. Louis Missouri. Dr. Young is also the author of numerous patents and publications.

RXI-109, currently in phase I clinical study, is RXi Pharmaceuticals self-delivering RNAi compound (sd-rxRNA

Tagged as: Advisory, appoints, Board, Experts, Medical, News, Pharmaceuticals, QualityStocks, Scientific, Seasoned